Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease

被引:0
|
作者
Tan, Youwen [1 ]
Zhang, Xinyue [1 ]
机构
[1] Zhenjiang Affiliated Jiangsu Univ, Hosp 3, Dept Hepatol, 300 Daijiamen, Zhenjiang 212003, Peoples R China
关键词
Chronic hepatitis B; non-alcoholic fatty liver disease; fatty hepatitis; liver fibrosis; non-alcoholic steatohepatitis; NAFLD; VALIDATION; SYSTEM;
D O I
10.1080/07853890.2024.2420858
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the diagnostic value of the FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis (NASH) in patients with chronic hepatitis B (CHB) with metabolic dysfunction-associated fatty liver disease (MAFLD). Methods: All patients with CHB and MAFLD who underwent liver biopsy at the Zhenjiang Third Hospital affiliated with Jiangsu University between August 2010 and December 2022 were included in the analysis. The diagnostic accuracy of FAST, NFS, FibroScan, and FIB-4 for diagnosing NASH and liver fibrosis were evaluated based on the area under the receiver-operating characteristic curve (AUC). Results: A total of 156 patients with CHB combined with MAFLD were included, including 69 with NASH and fibrosis stage 2 or higher (NASH+F >= 2), and 16 with NASH and cirrhosis (NASH+F4). The AUC of FAST, NFS, liver stiffness measurement (LSM), and FIB-4 for diagnosing NASH+F >= 2 was 0.739 (p < 0.001), 0.643 (p = 0.006), 0.754 (p < 0.001), and 0.665 (p = 0.003), respectively. The specificity of FAST, NFS, LSM, and FIB-4 was 67%, 51.8%, 78.6% and 76.8%, respectively, and the sensitivity was 75%, 78.6%, 67.9%, and 53.6%, respectively. No significant differences were found between groups. The AUC of FAST, NFS, LSM, and FIB-4 for diagnosing NASH+F4 was 0.650 (p = 0.038), 0.725 (p = 0.001), 0.851 (p < 0.001), and 0.560 (p = 0.533), respectively. The specificity of the FAST, NFS, LSM, and FIB-4 was 55.9%, 50.0%, 71.6%, and 75.5%, respectively and the sensitivity was 80.0%, 100%, 100%, and 50.0%, respectively. The differences between AUCs of FIB-4 and FAST compared with LSM were 0.291 and 0.201, respectively (p < 0.05). Conclusion: In patients with CHB combined with MAFLD, FAST did not have better accuracy than NFS and FIB-4 for predicting fibrotic NASH, whereas LSM had better accuracy than FAST and FIB-4.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure
    Takahashi, Tetsuya
    Watanabe, Tetsu
    Shishido, Tetsuro
    Watanabe, Ken
    Sugai, Takayuki
    Toshima, Taku
    Kinoshita, Daisuke
    Yokoyama, Miyuki
    Tamura, Harutoshi
    Nishiyama, Satoshi
    Arimoto, Takanori
    Takahashi, Hiroki
    Yamanaka, Tamon
    Miyamoto, Takuya
    Kubota, Isao
    HEART AND VESSELS, 2018, 33 (07) : 733 - 739
  • [32] External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients
    Jun, Dae Won
    Kim, Sang Gyune
    Park, Sang Hoon
    Jin, So-Young
    Lee, Ji Sung
    Lee, Jin-Woo
    Kim, Moon Young
    Choi, Dae Hee
    Cho, Yong Kyun
    Yeon, Jong Eun
    Sohn, Joo Hyun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (05) : 1094 - 1099
  • [33] Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease
    Petta, S.
    Ciminnisi, S.
    Di Marco, V.
    Cabibi, D.
    Camma, C.
    Licata, A.
    Marchesini, G.
    Craxi, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (04) : 510 - 518
  • [34] A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging
    Santiago-Rolon, Amarilys
    Purcell, Dagmary
    Rosado, Kathia
    Toro, Doris H.
    PUERTO RICO HEALTH SCIENCES JOURNAL, 2015, 34 (04) : 189 - 194
  • [35] The risk for colorectal adenoma is associated with liver fibrosis in patients with non-alcoholic fatty liver disease
    Kim, Min Cheol
    Jang, Byung Ik
    Cho, Joon Hyun
    Kim, Sung Bum
    Kim, Kook Hyun
    Lee, Si Hyung
    Kim, Tae Nyeun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 506 - 506
  • [36] Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
    Tacke, Frank
    Weiskirchen, Ralf
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [37] FIB-4 liver fibrosis index correlates with aortic valve sclerosis in non-alcoholic population
    Durak, Huseyin
    Cetin, Mustafa
    Emlek, Nadir
    Ergul, Elif
    Ozyildiz, Ali Gokhan
    Ozturk, Muhammet
    Duman, Hakan
    Yilmaz, Ahmet Seyda
    Satiroglu, Omer
    ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES, 2024, 41 (01):
  • [38] Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD)
    Tasneem, Abbas Ali
    Luck, Nasir Hassan
    Majid, Zain
    TROPICAL DOCTOR, 2018, 48 (02) : 107 - 112
  • [39] Metabolic Syndrome Is Associated With Advanced Liver Fibrosis Among Pediatric Patients With Non-alcoholic Fatty Liver Disease
    Ting, Yi-Wen
    Wong, Sui-Weng
    Zaini, Azriyanti Anuar
    Mohamed, Rosmawati
    Jalaludin, Muhammad Yazid
    FRONTIERS IN PEDIATRICS, 2019, 7
  • [40] Ultrasonographic grayscale findings related to fibrosis in patients with non-alcoholic fatty liver disease: comparison with transient elastography and Fib-4 index
    Matsumoto, Naoki
    Kumagawa, Mariko
    Ogawa, Masahiro
    Kaneko, Masahiro
    Watanabe, Yukinobu
    Nakagawara, Hiroshi
    Masuzaki, Ryota
    Kanda, Tatsuo
    Moriyama, Mitsuhiko
    Sugitani, Masahiko
    JOURNAL OF MEDICAL ULTRASONICS, 2021, 48 (03) : 323 - 333